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Histone acetyltransferases (HATs) are a group of  enzymes that 
acetylate lysine residues in histones, which are bound to DNA 
in all eukaryotes to form a complex and well organized structure 
called chromatin. HATs play an important role in regulating the 
chromatin organization and accessibility of  the DNA to the tran-
scriptional machinery by altering the acetylation status of  histones 
in particular gene loci by chromatin remodeling. Histone acety-
lation marks active gene transcription while lack of  acetylation 
marks gene repression. The –acetyl moieties are removed from 
the histones by Histone deacetylases (HDACs). Thus HATs and 
HDACs play a dynamic role in switching a gene ON and OFF.
Dysfunction and deregulation of  these enzymes leads to aber-
rant expression of  genes thereby affecting the cellular phenotype, 
resulting in diseases like cancer and neurodegenerative disorders 
[1,2]. Several proteins including transcription factors also undergo 
dynamic acetylation and deacetylation processesthat affects pro-
tein-protein interactions, protein-DNA interactions and cellular 
localization thereby changing the physiology of  the cell. Thus in 
several disease models HATs and HDACs are attractive targets 
for manipulating the gene expression by altering their activity by 
small molecule modulators.
In cancerous cells histone acetylation pattern in the chromatin 
is deregulated due to either i) improper targeting of  HATs and 
HDACs to a particular gene loci, ii) overexpression of  HDACs or 
iii) inactivation of  HAT activity due to mutations thereby causing 
aberrant gene expression. Restoring the expression of  genes aber-
rantly suppressed, required for normal cell physiology is the ba-
sis for development of  HDAC inhibitors as cancer therapeutics. 
Though acetylation/deacetylation determines the accessibility of  
DNA to transcription machinery in chromatin, HDAC inhibitors 
are known to affect only around 10% of  genes which importantly 
include genes that regulate cell cycle and apoptosis [1]. This abil-
ity makes them non-toxic to normal cells and hence attractive 
agents in chemotherapy. Several HDAC inhibitors like Romidep-
sin, SAHA, LBH589, Valproic acid, TSA etc., are in various stages 
of  clinical trials and hold promise as future drugs to treat cancer.
Recently Histone acetylation in brain cells has been linked to 
neuro-protection and memory functions. Several neurological 
disorders like Huntington’s disease (HD), Parkinson’s disease 
(PD), Alzheimer’s disease (AD) and Amyotrophic lateral sclero-
sis (ALS) are all associated with histone hypoacetylation. HD is 
characterized by progressive neurodegeneration (loss of  neurons) 
that is linked to the product (PolyQ htt) of  CAG repeat expan-
sion in Huntingtin gene sequestering and inhibiting HATs- p300 
and CBP. Several cellular and animal HD-models have shown to 
be associated with decreased Histone H3 acetylation level (in par-
ticular H3K9 and H3K14)[3]. In PDα-synuclein, a nuclear protein 
promotes neurotoxicity by binding and masking histones thereby 
blocking acetylation [4]. AD is associated with abnormal acetyla-
tion of  Tau protein and over expression of  amyloid β precursor 
protein (APP) that leads to decreased CBP levels and thereby re-
duced histone H3 and H4 acetylation [5]. Histone deacetlylases 
are shown to be aberrantly upregulated in neurons of  brain from 
ALS patients [6]. Albeit the differences in pathophysiology, aber-
rant acetylation/deacetylation seems to be the hallmark of  neu-
rological disorders.Thus HDAC inhibitors were considered as 
therapeutics in order to restore the acetylation levels and thereby 
gene expression in neuropathic conditions. Recent studies have 
implicated histone epigenetic modifications, in particular histone 
acetylation, in learning, memory retrieval and synaptic plastic-
ity. In animal models Histone acetylation levels were shown to 
increase in hippocampus immediately after training. In animal 
models systemic administration of  HDAC inhibitor – Sodium 
Butyrate was shown to enhance memory while intrahippocampal 
injection of  TSA immediately after training enhanced long term 
memory further confirming the positive role of  histone acetyla-
tion in gene regulation required for learning and memory in brain.
Despite several studies and clinical trials with HDAC inhibitors 
as therapeutic interventions for various cancers and neurologi-
cal disorders, scientists are skeptical about their use because of  
their non-specific nature and detrimental effects of  long term use. 
Also there are as many as eighteen HDACs identified to date with 
functional redundancy and often associated as a complex rather 
than functioning individually which makes specific targeting im-
possible. Recently a new class of  molecules – “HAT activators” 
has been discovered with ability to induce hyperacetylation by ac-
tivating HATs.
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An amide derivative of  HAT inhibitor Anacardic acid – N-(4-
chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-ben-
zamide (CTPB) was shown to specifically activate p300 but not 
p300/CBP-associated factor (PCAF) in vitro. However, the use 
of  CTPB to activate HATs in vivo was not possible because of  
its cell permeability, which was overcome by nanoparticle delivery 
[7]. Further an analog of  CTPB, N-(4-chloro-3-trifluoromethyl-
phenyl)-2-ethoxy-benzamide (CTB) that lacks the pentadecyl 
-side chain was shown to alter the structure of  p300 thereby en-
hancing its enzymatic activity [8]. CTB was also shown to increase 
acetylation of  p53 in MCF7 breast cancer cells. Nemorosone 
a polyisoprenylated benzophenone from natural sources was 
shown to selectively bind to and enhance the acetyltransferase ac-
tivity of  p300/CBP in vitro as well as in cell culture models [9]. 
Pentadecylidenemalonate a simple derivative of  Anacardic acid 
was shown to enhance PCAF activity while inhibiting p300/CBP 
in vitro. [10] Remarkably cell permeability, HAT enhancing ability 
and anti-proliferative activity of  CTB, Nemorosone and Pentade-
cylidenemalonate make them attractive leads for development of  
anticancer drugs. Recently, TTK21 a p300/CBP activator, con-
jugated to glucose based carbon nanosphere when administered 
intra-peritoneal enhanced histone acetylation in hippocampus the 
main learning and memory center and frontal cortex of  brain.
Incidentally hippocampus is the first part of  brain to undergo 
neurodegeneration in AD. TTK21 enhanced differentiation and 
maturation of  hippocampal neurons thereby promoting long 
term memory [11].
HAT activators and HDAC inhibitors have the potential to be-
come future therapeutics playing crucial role in restoring histone 
acetylation levels in disease conditions associated with hypoacety-
lation. Also, it would be interesting to study the synergistic effects 
of  HAT activators and HDAC inhibitors in order to achieve mini-
mum toxicity and optimal effect which requires identification and 
characterization of  bigger library of  small molecules to choose 
from.
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